Getting new medicines and therapies to patients faster
To accelerate and simplify the complex journey of drug discovery and development, Thermo Fisher launched our Accelerator™ Drug Development solution in 2024. This truly unique offering leverages our unparalleled capabilities to provide a customizable suite of manufacturing, clinical research and clinical supply chain services to emerging biotechs and large pharmaceutical companies.
Accelerator™ Drug Development supports our customers at every stage of the critical drug development process, enabling them to improve their return on R&D investments while improving the lives of patients in need.
"Thermo Fisher is transforming drug development and manufacturing processes to support customers as they move critical programs forward to tackle global health challenges with speed, quality, and efficiency.”
— Mike Shafer, Executive Vice President and President, Biopharma Services, Thermo Fisher Scientific
A more personalized approach to cancer treatment
To help accelerate research into new treatments for acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), Thermo Fisher has partnered with the National Cancer Institute on the myeloMATCH (Molecular Analysis for Therapy Choice) precision medicine umbrella trial. MDS is a group of blood disorders characterized by abnormal production of blood cells in bone marrow, which can progress to AML — one of the most common types of leukemia. An aggressive cancer, it has a five-year survival rate of only 30% to 40% for individuals under age 60. Rapid detection and effective treatment are essential to improve patient outcomes.
The myeloMATCH study will use our Ion Torrent™ Genexus™ System, a next-generation sequencing instrument, to test patients’ bone marrow and blood for specific genetic biomarkers. The system is designed to deliver results in a single day, enabling clinical sites to more quickly match patients with appropriate clinical trials based on their unique cancer profile.
Expanding access to advanced cancer diagnostics
To increase patient access to affordable, advanced genomic testing for cancer, Thermo Fisher is collaborating with the National University Hospital, Singapore (NUH), and Mirxes, a Singapore-headquartered RNA technology company, to develop next-generation sequencing testing solutions. By advancing cancer research tailored to addressing the needs of the Southeast Asian population, we can support healthcare providers in more rapidly selecting targeted therapy for individual patients.
"NUH's deep clinical expertise combined with the cutting-edge advancements of biotechnology capabilities and research holds immense promise for the future of cancer care. This collaborative approach will empower us to refine early detection methods and deliver even more precise diagnoses and treatments, propelling us towards optimized clinical outcomes in the fight against cancer.”
— Tan Soo Yong, Associate Professor, Head & Senior Consultant, Department of Pathology, NUH
A once-in-a-decade innovation
To support everything from clean energy to quantum computing, Thermo Fisher launched the groundbreaking Thermo Scientific™ Iliad™ Scanning Transmission Electron Microscope. The Iliad offers a seamless and user-friendly workflow that integrates a number of our advanced analytical technologies, including electron energy loss spectroscopy (EELS), which can — among other things — analyze lithium, a key component in battery development. The Iliad incorporates our most innovative high-resolution spectrometer to accurately determine the composition of materials, as well as our proprietary energy filter for detailed imaging and chemical analysis of samples. This technology provides researchers with deeper insights into the chemical nature of the most sophisticated materials, down to the atomic level.
“It’s one thing to write papers on EELS quantification, it is far more exciting to see these ideas also implemented in a product that will really change the user experience.”
— Jo Verbeeck, Professor, University of Antwerp